Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disorder described by interminable, dynamic scarring of the lungs and the pathological sign of normal interstitial pneumonia. The interstitial lung diseases (ILDs) are a heterogeneous collection of parenchymal lung ailments described by shifting degrees of inflammation and fibrosis. A portion of these may occur secondary to a known precipitant, for example, drugs, immune system connective tissue disease, hypersensitivity to breathed in natural antigens, or sarcoidosis, while others, the idiopathic interstitial pneumonia (IIPs), have no recognizable reason. Idiopathic pneumonic fibrosis (IPF) is one of the most forceful types of IIP, described by chronic, progressive fibrosis related with a relentless decrease in lung functionality, progressive respiratory failure, and high mortality. It is a lung issue where there is scarring of the lungs from an obscure reason. It is generally a progressive sickness with a long-term prognosis. The exemplary highlights of the disorder incorporate progressive dyspnea and a non-productive cough. Pneumonic capacity tests ordinarily uncover prohibitive disability and decreased carbon monoxide diffusing limit.
Idiopathic pulmonary fibrosis: Epidemiology Insights
The Report Ocean will provide insights for epidemiology based on segmentation of Idiopathic pulmonary fibrosis on the basis of following parameters:
- Total Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
- Total Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
- Gender-specific Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
- Age-specific Diagnosed Prevalent Population of Idiopathic pulmonary fibrosis in 9MM
Idiopathic pulmonary fibrosis has an estimated prevalence of 13 to 20 per 100,000 people worldwide. About 100,000 people are affected in the United States, and 30,000 to 40,000 new cases are diagnosed each year. Familial pulmonary fibrosis is less common than the sporadic form of the disease.
It was found in studies that an overall prevalence of IPF of 13.2 per 100,000 for women and 20.2 per 100,000 for men. People aged ≥65 years observed IPF rates higher than younger population. Within a period of 10 years, the incidence plateaued while prevalence increased for IPF cases. It was concluded that higher prevalence and incidence rates of IPF are among men and with increasing age, especially after 75 years.
The specific etiology for the development of IPF is obscure, however risk factors like exposure to tobacco smoke, wood, metal, viral diseases, dust, a family background of IPF and gastroesophageal reflux have been embroiled. The current hypothesis on the etiology of IPF is that repetitive injury to the alveolar epithelium triggers a cascade of signalling by the immune system prompting fibrosis. A dysregulated reaction to the injury can cause tissue redesigning. Additionally, in IPF patient’s lung epithelium is believed to be broken, and genetically susceptible to atypical reaction to injuries. The onset of IPF is likely brought about by multiple mechanisms.
Market for Idiopathic pulmonary fibrosis
In U.S alone, the prevalent population of Idiopathic Pulmonary Fibrosis is 1,05,544 in 2019. The global Idiopathic pulmonary fibrosis market generated US$1,768.8 million in 2019 and is projected to reach US$2,859.8 million by 2025 and to US$ 4,298.8 million by 2030, growing at a CAGR of 9.4% from 2017 to 2030.
This report forecasts growth of Idiopathic pulmonary fibrosis market at global level and provides an insight of the latest industry in the forecast period 2017-2030. For the current analysis, Report Ocean has segmented the market by drug type.
- Drug Type
- MAPK inhibitors
- tyrosine kinase inhibitors
- Autotaxin inhibitors
Rising prevalence of IPF is expected to elevate the market. According to the National Institutes of Health (NIH), approximately 40,000 new cases of IPF are diagnosed each year. Furthermore, commercialization of new drugs and rise in cigarette smoking population are some factors which results in escalated demand for IPF treatment and thus leads to market expansion. However, certain factors will hamper industry growth to certain extent. These include the complicated diagnosis and high cost of treatment.
Esbriet (MAPK Inhibitor) by F. Hoffman La Roche and Ofev (Tyrosine Kinase Inhibitor) by Boehringer Ingelheim International GmbH are the only drugs approved by the Food and Drug Administration (FDA) for the treatment of IPF. Both these drugs slow down the death rate in patients with IPF. Among drug class, MAPK Inhibitors (Esbriet) holds the maximum share in the market. Esbriet was the first drug approved in 2011 in Europe for treating mild to moderate IPF and in 2014 in the U.S. for IPF. It is a major drug due to a well-established safety profile. Tyrosine Kinase Inhibitors (OFEV) is expected to grow in market over the forecast period owing to the priority review by the FDA.
North America is the leading region in the IPF treatments market in 2019 due to increasing prices of the drugs, accelerated approvals of the drugs in the U.S. and increasing prevalence of IPF.
Increasing number of IPF cases coupled with rising awareness has stimulated the demand of its treatment. Some of the known players are Genentech, Inc., Boehringer Ingelheim Pharma GmbH and Co. Kg, F. Hoffmann-La Roche, FibroGen, Inc., Promedior, Inc., Merck & Co., Inc., Galapagos NV, Biogen, Bristol-Myers Squibb Company, Prometic Life Sciences Inc. and others.
Commercialized protocols and products
Esbriet is a prescription medicine used to treat idiopathic pulmonary fibrosis (IPF). Esbriet was originally developed by InterMune Inc., which later merged with Roche. Esbriet is currently marketed and investigated by Genentech (A Roche Company). Esbriet was developed for use by InterMune in the United States, Europe and other countries. It was granted marketing authorization in the European Union (EU) in 2011 for the treatment of adults with mild to moderate IPF.
OFEV is a prescription medicine used to treat people with a lung disease called idiopathic pulmonary fibrosis (IPF), to treat people with a chronic interstitial lung disease in which lung fibrosis continues to worsen and to slow the rate of decline in lung function. It was developed by Boehringer Ingelheim Pharma GmbH and Co. Kg. Ofev’s active ingredient nintedanib is a tyrosine kinase inhibitor (TKI) that inhibits the growth factor receptors involved in the progress of pulmonary fibrosis.
FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF) by FibroGen, Inc. has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).
About Report Ocean:
We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.
Have Any Query? Ask Our Experts: https://www.reportocean.com/industry-verticals/sample-request?report_id=BWCC44
Get in Touch with Us:
Name: Nishi Sharma
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)